Volume | 1 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
International Stem Cell Corporation (QB) | ISCO | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.097 | 0.097 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
1 | 1 | - | 0.046 - 0.167 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:07:51 | 1 | $ 0.09 | USD |
International Stem Cell Corporation (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
800.44k | 8.00M | 2.19M | 7.79M | -131k | -0.02 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
International Stem Cell (QB) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ISCO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.097 | 0.097 | 0.09 | 0.0964387 | 424 | 0.00 | 0.00% |
1 Month | 0.109 | 0.109 | 0.0612 | 0.0967865 | 2,507 | -0.012 | -11.01% |
3 Months | 0.10 | 0.12 | 0.0521 | 0.0916107 | 1,966 | -0.003 | -3.00% |
6 Months | 0.11 | 0.15 | 0.046 | 0.0947268 | 2,870 | -0.013 | -11.82% |
1 Year | 0.133 | 0.167 | 0.046 | 0.1163791 | 3,173 | -0.036 | -27.07% |
3 Years | 0.441 | 0.80 | 0.046 | 0.389305 | 5,596 | -0.344 | -78.00% |
5 Years | 1.14 | 1.20 | 0.046 | 0.5138044 | 5,637 | -1.04 | -91.49% |
International Stem Cell (QB) Description
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). |